BTIG raised the firm’s price target on Exact Sciences (EXAS) to $75 from $65 and keeps a Buy rating on the shares. The firm notes shares of Exact Sciences are up following news that the company obtained a price of about $592/test for Cologuard Plus, or a 16% price increase compared to its first generation Cologuard test. BTIG says that while the firm and most investors expected some price increase for Cologuard Plus, the actual amount and mechanism of the increase was uncertain, with today’s news helping to derisk the stock.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences price target raised to $86 from $82 at TD Cowen
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS
- Exact Sciences to present abstracts on multi-cancer early detection test
- Exact Sciences price target lowered to $75 from $85 at Piper Sandler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
